

Year	Lymphomas (C81-86)	Malignant immunoproliferative diseases (C88)	Multiple myeloma and malignant plasma cell neoplasms (C90)	Leukaemia (C91-C95)	Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)
2015	69	<5	19	32	5
2016	84	5	31	39	<5
2017	99		35	31	
2018	107	<5	28	58	<5
2019	92	<5	46	70	
2020	80	<5	48	47	
2021	92	<5	38	55	<5
2022	84		23	60	
2023	75	<5	38	79	
2024	80		33	59	
2025	59	<5	15	43	

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.